These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28259587)

  • 1. Justifying high drug prices within the context of value: Biologics versus generics.
    Patterson ME; Rosenfelt DJ
    Res Social Adm Pharm; 2018 Feb; 14(2):121-123. PubMed ID: 28259587
    [No Abstract]   [Full Text] [Related]  

  • 2. A few specialty drug prices fall--all generics.
    Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
    [No Abstract]   [Full Text] [Related]  

  • 3. Authorized generic drugs, price competition, and consumers' welfare.
    Berndt ER; Mortimer R; Bhattacharjya A; Parece A; Tuttle E
    Health Aff (Millwood); 2007; 26(3):790-9. PubMed ID: 17485758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generics prices in SA compare well with those in other countries.
    S Afr Med J; 2005 Feb; 95(2):88. PubMed ID: 15751196
    [No Abstract]   [Full Text] [Related]  

  • 5. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
    Kuhrt K
    IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockbusters for cheap? The difficulties surrounding generic biologics.
    Josephson SA; Johnston SC; Hauser SL
    Ann Neurol; 2013 Sep; 74(3):A7-8. PubMed ID: 24115256
    [No Abstract]   [Full Text] [Related]  

  • 7. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 10. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The industry recommends increased use. Biosimilars are like generics, but still not].
    Bergström R; Nyblom K
    Lakartidningen; 2010 Oct 20-26; 107(42):2584-5. PubMed ID: 21137555
    [No Abstract]   [Full Text] [Related]  

  • 12. Future pharmacists and public initiatives to control retail drug prices: a political economy framework.
    Pelton LE; Strutton D; Smith MC
    Health Mark Q; 1993; 10(3-4):241-59. PubMed ID: 10127923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obama budget aims to lower biologics exclusivity period.
    Future Med Chem; 2011 Mar; 3(4):395. PubMed ID: 21452975
    [No Abstract]   [Full Text] [Related]  

  • 14. Price and welfare effects of a pharmaceutical substitution reform.
    Granlund D
    J Health Econ; 2010 Dec; 29(6):856-65. PubMed ID: 20832130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paying physicians to prescribe generic drugs and follow-on biologics in the United States.
    Sarpatwari A; Choudhry NK; Avorn J; Kesselheim AS
    PLoS Med; 2015 Mar; 12(3):e1001802. PubMed ID: 25781468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market watch: Sales of biologics to show robust growth through to 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
    [No Abstract]   [Full Text] [Related]  

  • 17. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
    Kuhrt K; Chace-Ortiz M
    IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules.
    Scott Morton F
    Rand J Econ; 1997; 28(2):269-90. PubMed ID: 11794358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Shortages in the United States: Are Some Prices Too Low?
    Hernandez I; Hershey TB; Donohue JM
    JAMA; 2020 Mar; 323(9):819-820. PubMed ID: 32125409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.